Hormone Replacement Therapy (HRT): Comprehensive Clinical Overview

Executive Summary: Hormone replacement therapy (HRT) involves administering deficient hormones (most commonly oestrogen and progesterone in women, or testosterone in men) to alleviate symptoms of hormone loss and prevent associated complications[1][2]. In menopausal women (especially <60 years or within 10 years of menopause), HRT effectively relieves vasomotor and urogenital symptoms and maintains bone density[3][4]. Preparations include systemic oestrogens (oral tablets, patches, gels, sprays) often with a progestogen if the uterus is present, plus alternatives (vaginal oestrogen, tibolone, testosterone) and for thyroid replacement (levothyroxine) or other endocrine deficits[2][5]. Benefits (symptom control, fracture risk reduction, possible metabolic advantages) must be weighed against risks (breast and endometrial cancer, venous thromboembolism (VTE), stroke) which vary by age, timing, dose, and route[6][7]. Current guidelines (NICE, ESE, Endocrine Soc, British Menopause Soc.) stress individualized decision-making and informed consent[8][9]. Therapy is reviewed at 3 months and annually[10], adjusting dose or approach as needed. Non-hormonal alternatives (lifestyle, SSRIs/SNRIs, gabapentin, lubricants, CBT) may be used if HRT is unsuitable or declined. Special populations (older women, cancer survivors, transgender individuals, clotting disorders) require tailored risk/benefit consideration. No arbitrary upper time-limit is mandated; duration is guided by ongoing symptom benefit versus risk[11]. This report details definitions, mechanisms, indications, evidence-based benefits and harms, monitoring, counselling points and practical prescribing advice for HRT, with comparisons of formulations, indications, benefits and monitoring (see Tables).

Definition and Physiological Rationale

Hormone replacement therapy (HRT) refers to giving exogenous hormones to replace those the body no longer makes in sufficient amounts[1][2]. For example, oestrogen (often with progesterone) is given to post‑menopausal women who produce little ovarian hormone[1][2]. Likewise, testosterone is replaced in male hypogonadism, and levothyroxine is given in hypothyroidism. The physiological rationale is that hormones (sex steroids, thyroid, etc.) have key roles in bone maintenance, cardiovascular function, cognition, metabolism and sexual health. Menopause-induced oestrogen loss causes vasomotor instability (hot flushes), genitourinary atrophy (vaginal dryness, urinary symptoms) and accelerated bone resorption; HRT mitigates these deficits. In men, testosterone maintains libido, muscle and bone mass; in thyroid deficiency, thyroxine sustains metabolic rate. Thus, HRT aims to restore near-physiological hormone levels to relieve symptoms (e.g. hot flushes, mood swings) and prevent long-term consequences (osteoporosis, dyslipidaemia)[9][5]. (Other endocrine replacements such as cortisol for Addison’s disease or growth hormone for pituitary deficiency are conceptually similar “replacement” therapies[1].)

Types of HRT: Hormones and Formulations

• Oestrogens: In HRT this usually means 17β-oestradiol or conjugated equine oestrogens. Forms include oral pills (micronized estradiol, conjugated estrogens), transdermal patches/gels/sprays, vaginal rings/tablets/creams. Transdermal (patch/gel/spray) avoids first-pass liver metabolism, producing steadier levels and no increased VTE risk[12], but may cause skin irritation. Oral oestrogens are effective and convenient but raise clotting factors and triglycerides, modestly increasing VTE/stroke risk compared to transdermal[13][6]. Vaginal oestrogen (low-dose cream, ring or tablet) provides local relief of genitourinary symptoms with minimal systemic absorption and is safe in women who cannot take systemic HRT[14]. Common systemic doses (unspecified here) might be roughly equivalent to 50–100 µg transdermal patch or 1–2 mg oral estradiol, but practice is individualized.
• Progestogens: Natural micronized progesterone or synthetic progestins (e.g. medroxyprogesterone acetate, norethindrone) are given to any woman with an intact uterus to prevent endometrial hyperplasia/cancer. Available as oral pills, injectables (e.g. depo), or an intrauterine system (IUS; e.g. levonorgestrel coil). Continuous combined therapy (daily progestogen) better protects the endometrium than cyclical dosing[15]. Side effects include breast tenderness, mood changes, spotting or bloating[16]. (Women without a uterus receive oestrogen alone.)
• Testosterone: Used in male hypogonadism (injectable, transdermal gel/patch/pellet) and, off‑label, in some postmenopausal women with hypoactive sexual desire. Formulations include intramuscular injections or daily transdermal gels. Testosterone improves libido, energy and muscle strength in deficient men and can modestly improve sexual function in women[17]. Key risks of testosterone therapy are erythrocytosis (in men) and androgenic effects (acne, hair growth, clitoral enlargement in women)[17][18]. Guideline dosing targets physiological mid-normal male levels; levels and hematocrit are monitored periodically[19].
• Thyroid hormones: Levothyroxine (T4) is standard for hypothyroidism (“thyroid replacement”). Doses are titrated to normalize TSH. Liothyronine (T3) may be used in combination. Monitoring is by TSH, not typically grouped under “HRT” but it is hormone replacement.
• Others: Glucocorticoid replacement (hydrocortisone, prednisone) in adrenal insufficiency; growth hormone in GH deficiency; mineralocorticoids in Addison’s. These are lifesaving but have their own guidelines beyond scope here[1].

Formulation Comparison (examples): (See Table 1.)

Formulation	Examples / Hormone	Indications	Pros	Cons / Risks
Oral oestrogen pills	Micronized 17β-estradiol, conjugated estrogens	Systemic menopausal symptoms, POI	Easy dosing; wide availability; effective symptom relief	First-pass liver effects ↑ clotting factors, ↑ triglycerides[13]; higher VTE/stroke risk than patch[12]; possible nausea
Transdermal estrogen (patch/gel/spray)	17β-estradiol transdermal patch, gel	Same as above, especially if VTE risk	Avoids first-pass; steady levels; no increase in VTE risk[12]; skin application easy for many.	Skin irritation; adherent issues; cost higher.
Vaginal estrogen	Estradiol ring/tablet/cream, estriol cream	Genitourinary atrophy (vaginal dryness, urinary symptoms)	Local effect, minimal systemic absorption (no progestogen needed)	Local irritation, discharge; does not relieve hot flashes or systemic symptoms.
Combined HRT (oral or patch with progestogen)	Any estrogen + daily progestogen (e.g. MPA, norethisterone, levonorgestrel IUS)	Women with uterus for symptom relief	Relieves systemic symptoms and protects endometrium (with progestin)	Combined therapy slightly higher breast cancer risk than estrogen-only[7]; progestogen side effects (mood, bleeding).
Progesterone IUS	Levonorgestrel-releasing coil (Mirena)	Endometrial protection during HRT	Very effective endometrial protection; minimal systemic progestin side effects	Insertion procedure; irregular bleeding initially; expulsion risk.
Testosterone gel/patch (women)	300 µg/day estradiol + low-dose testosterone patch (female use, unlicensed)	Postmenopausal women with HSDD (after HRT trial)	Improves sexual desire/function[17]; can be added to HRT for hypoactive desire	Hirsutism, acne; virilization at higher doses; not approved/licensed for women in many countries[18].
Levothyroxine (oral)	T4 25–200 µg tablets (dose by weight/TSH)	Hypothyroidism	Established therapy; low cost; once daily dosing; normalizes metabolism	Over-replacement → arrhythmia, bone loss; under→persisting hypothyroid symptoms.

Indications

HRT is indicated whenever hormone deficiency causes significant symptoms or health risks:

• Menopause (natural or surgical): The commonest use. HRT (menopausal hormone therapy) is indicated for vasomotor symptoms (hot flushes, night sweats), genitourinary syndrome (vaginal dryness, dysuria), mood symptoms and prevention of osteoporosis after menopause[5][9]. Systemic HRT is recommended for bothersome menopausal symptoms in women under 60 or within 10 years of menopause[9][20]. If only genitourinary symptoms occur, local (vaginal) oestrogen or moisturizers may suffice[14][21].
• Premature Ovarian Insufficiency (POI, menopause <40): HRT is mandatory to replace ovarian hormones until the age of natural menopause (about 51)[22][23]. This restores normal development and protects bone and cardiovascular health. (Oestrogen plus progestogen is given in 46,XX chromosomal or surgical POI.)
• Hypogonadism in Men: Testosterone replacement is indicated for symptomatic testosterone deficiency (low libido, erectile dysfunction, low muscle mass) in confirmed male hypogonadism (primary or secondary)[24]. Therapy aims for mid-normal male testosterone levels, improves energy, libido and bone density.
• Hypogonadism in Women: In certain conditions (e.g. Turner syndrome, post‑oophorectomy, GnRH analogue therapy), oestrogen/progestogen HRT is given until natural menopause. For refractory low libido (hypoactive sexual desire disorder) in postmenopausal women, after other causes are ruled out, adding testosterone can be considered[25][17] (though usually only after trying conventional HRT[25]).
• Transgender Individuals: For male-to-female (MTF) transgender patients, feminizing hormone therapy uses oestrogens (often plus an anti-androgen) to induce female secondary characteristics[24]. For female-to-male (FTM) patients, masculinizing therapy uses testosterone to suppress oestrogen and induce male changes[24]. (These regimens are part of gender-affirming care.)
• Other Endocrine Deficiencies: Hypothyroidism (levothyroxine), adrenal insufficiency (glucocorticoid/mineralocorticoid), growth hormone deficiency, etc., are not usually termed “HRT” but represent hormone replacement for specific endocrine disorders[1].

Evidence-based Benefits and Efficacy

HRT has well-documented symptomatic and health effects:

• Vasomotor Symptom Relief: Systemic HRT is the most effective treatment for menopausal hot flashes and night sweats. RCTs (e.g. PEPI) show that oestrogen ± progestogen markedly reduce vasomotor frequency and severity (OR≈0.4 vs placebo)[26]. Guidelines agree it should be offered to women with moderate–severe vasomotor symptoms[9][26].
• Urogenital / Sexual Health: Oestrogen (systemic or especially local vaginal) greatly improves vulvovaginal atrophy: it thickens vaginal epithelium, relieves dryness and dyspareunia, and can reduce urinary urgency/UTI risk. Adding testosterone may enhance libido in women with true hypoactive desire[17]. In men, testosterone improves erectile function and libido in hypogonadal men (Endocrine Society).
• Bone Health: HRT consistently preserves bone density and reduces fracture risk. Meta-analyses show HRT users have significantly fewer osteoporotic fractures than non-users[27][4]. NICE notes fragility fracture risk is “decreased while taking HRT” (with the benefit maintained during treatment)[4]. Thus HRT is an option for osteoporosis prevention/treatment in menopausal women, especially younger ones, often delaying the need for other agents.
• Cardiovascular Effects: The relationship is complex (the “timing hypothesis”). In women <60 or within 10 years of menopause, oestrogen may improve lipids and vessel function. Some data suggest early use may reduce coronary disease risk, whereas starting HRT in older women (≥60) may increase risk[6][28]. Current guidelines state HRT should not be used solely to prevent cardiovascular disease[28]. NICE found no overall increase in coronary heart disease or cardiovascular mortality with combined HRT[29]. HRT may slightly lower type 2 diabetes incidence[30]. However, transdermal oestrogen avoids negative effects on clotting.
• Metabolic Effects: By reducing visceral fat and improving insulin sensitivity, HRT appears to modestly reduce new-onset type 2 diabetes (statistically significant in meta-analysis[27]). It also tends to improve lipid profiles (raised HDL, lower LDL) unless progestogen counteracts it.
• Cognitive and Mood: Evidence is mixed. HRT can improve perimenopausal mood lability in some women, but it is not indicated to treat depression or dementia[31]. RCTs show no cognitive benefit of HRT in older women, and a late start (≥65) may even slightly raise dementia risk[31][32]. Thus HRT is not used for cognitive protection.
• Quality of Life: Multiple studies and guidelines report that HRT markedly improves quality of life by relieving menopausal symptoms. The balance of evidence shows that for symptomatic women under age 60 or within 10 years of menopause, the benefits (symptom relief, bone) generally outweigh risks[33][9].

Table 2 (see below) summarises comparative benefits and risks of combined vs oestrogen-only HRT.

Risks, Contraindications and Side Effects

Risks: Key risks of systemic HRT include:

• Breast Cancer: Combined oestrogen–progestogen therapy carries a small increased risk of invasive breast cancer that grows with duration of use[7]. Estimates are on the order of +3–6 cases per 1,000 women over 5–10 years[7]. Oestrogen-only therapy (in women with hysterectomy) has little or no increase in breast cancer risk[34]. Importantly, any excess risk declines after stopping HRT (though may persist for years)[7]. Mortality from breast cancer does not appear to rise with HRT[35].
• Endometrial Cancer: Unopposed oestrogen (in a woman with a uterus) markedly increases endometrial cancer risk. Adding progestogen in HRT (continuous or cyclic) largely prevents this. Continuous combined HRT actually reduces endometrial cancer risk compared to no HRT[36]. Cyclical/progestogen withdrawal regimens carry a slightly higher risk, especially with longer use and fewer progestogen days[37].
• Ovarian Cancer: There is a very slight increase in ovarian cancer with HRT[38], but the absolute risk is very low. (NICE notes a small increase “in people with ovaries”[38].)
• Venous Thromboembolism (VTE): Oral oestrogen increases VTE (DVT/PE) risk roughly twofold (from a baseline of ~1–2 per 1,000/year)[39][13]. This risk is highest in the first year and in older women. In contrast, transdermal HRT does not raise VTE risk[13] (because it avoids liver activation of clotting factors[40]). Tibolone (synthetic steroid) may also have lower VTE risk. Thrombotic risk is additive with other factors (age, obesity, immobility, thrombophilia, smoking).
• Stroke: Oral HRT in older (>60) women can raise ischaemic stroke risk; transdermal appears safer[41][13]. NICE notes stroke risk is “unlikely to increase” with transdermal use[42], whereas higher-dose or late-start oral HRT does raise risk[42]. Overall stroke rates remain low in women <60.
• Cardiovascular Disease: Large trials (WHI and others) show no net increase in heart attack or overall mortality with HRT in younger postmenopausal women[29][13]. In fact, the cardiovascular mortality was unchanged with combined HRT[29]. However, starting HRT in women with existing CHD or beyond age 60 may increase risk[6][28], so guidelines caution against late initiation purely for cardioprotection.
• Cognitive/Dementia: In women ≥65, combined HRT may increase dementia risk[32]; there is no evidence that HRT prevents cognitive decline[31].
• Other Risks: Long-term HRT has been associated with a small increase in gallstones, cholecystitis and (with some progestogens) weight gain. Oestrogen can worsen migraines or headache. Thyroid replacement (levothyroxine) generally has minimal risk if dosed to keep TSH normal; overtreatment can lead to atrial fibrillation or osteoporosis.

Contraindications: Guidelines cite the following contraindications (especially for oestrogen therapy)[43]：

• Known or suspected hormone-sensitive cancer (e.g. breast, endometrial)[43][44]. Systemic HRT is contraindicated in active breast cancer or endometrial cancer.
• Unexplained uterine bleeding until investigated (could indicate cancer or hyperplasia).
• History of VTE/PE or high-risk thrombophilia (e.g. factor V Leiden). (In some high-risk cases, transdermal oestrogen at low dose may be considered[45].)
• Stroke or Coronary Events in the past year.
• Uncontrolled hypertension or severe liver disease. (Milder hypertension is not an absolute contraindication[46].)
• Migraine with aura: A relative contraindication to oral HRT; transdermal is preferred if HRT is needed[47].

Strictly, “absolute” contraindications are few – some endocrinologists say none (in palliative cases)[48] – but in practice the above are treated as such. For progesterone-only therapy or vaginal oestrogen, many contraindications do not apply (e.g. low-dose vaginal oestrogen is safe even in breast-cancer survivors for local symptoms[21]).

Risk Modifiers: Key factors altering HRT risk-benefit include:

·       Age and Timing: Younger (<60) women or those <10 years since menopause have more benefit and less risk[20][6]. Starting HRT >10 years after menopause or >60 years old confers higher stroke and CHD risk[6][32].

·       Dose: Use the lowest effective dose. Higher doses carry proportionally higher risk (e.g. stroke with high-dose oestrogen[49]).

·       Route: Oral versus transdermal matters. Transdermal (patch/gel) is safer in terms of VTE and possibly stroke[13][42]. Oral oestrogens raise SHBG and CRP; patches do not.

·       Progestogen Type: Synthetic progestins (MPA) may have a different risk profile than micronized progesterone. Some evidence suggests micronized progesterone or dydrogesterone may have a lower thrombotic risk, but NICE notes evidence is still inconclusive[50].

·       Personal/Family History: A strong family history of breast cancer raises concern about HRT’s small added breast risk. Obesity (BMI>30) and smoking increase HRT’s relative risks (especially VTE). Comorbidities (diabetes, dyslipidaemia) do not preclude HRT but warrant careful consideration; transdermal is usually preferable in these cases[51][45].

Common Side Effects: Many side effects mirror menopause symptoms or appear transiently as the body adjusts. These include breast tenderness or engorgement, headache, nausea, bloating, mood swings, breakthrough vaginal bleeding or spotting, leg cramps and acne[52][16]. These occur in perhaps 10–20% of starters and often abate within 2–3 months. A period of adjustment (3–6 months) is recommended before switching therapies if tolerable. Persistent or heavy vaginal bleeding >6 months on HRT should be investigated[53][54]. Importantly, most women do not gain significant weight from HRT[55].

Table 3 (below) summarises risks and contraindications by formulation.

Monitoring and Follow-up

Follow-up for patients on HRT includes:

·       Initial Review: Re-evaluate at about 3 months after starting or changing HRT to assess symptom control and side effects[10]. Adjust dose or switch formulation if needed.

·       Ongoing Review: Annually thereafter[10] (or sooner if problems). At each visit, review vasomotor/genitourinary symptoms, mood/sexual concerns, side effects, bleeding patterns and overall risk factors. Reassess whether HRT is still needed. Continual symptom tracking (e.g. using a diary or MENQOL questionnaire) can be helpful.

·       Physical Exam: Check blood pressure, weight/BMI and breast exam at baseline and regular intervals. Ensure age-appropriate health screening (mammograms, cervical smears, bone density scanning if indicated). NICE specifically advises keeping menopausal women up to date with all routine national screening[56].

·       Laboratory Tests: No routine hormone levels (oestrogen/progesterone) are required to monitor HRT response[57]. Instead, clinical response is the guide. Baseline and periodic tests may include: fasting lipids and glucose (especially if metabolic risk factors), LFTs if oral oestrogen is used long-term, and bone density (DEXA) every few years if osteoporosis is a concern.

·       Specific Monitoring: For combined HRT, ensure progestogen is taken correctly (e.g. check that withdrawal bleeds occur on cyclical regimens). After 1–2 years on progestogen-containing HRT, endometrial surveillance is usually by symptoms (reporting bleeding) rather than routine ultrasound. For testosterone therapy in men, measure serum testosterone and haematocrit 3–6 months after initiation and then annually[19] (target mid-normal levels; stop if haematocrit >54%). In women on testosterone, monitor for virilization signs and serum levels as appropriate. For thyroid replacement, measure TSH 6–12 weeks after dose changes until stable.

Table 4 (below) summarises a monitoring schedule for different HRT types.

Alternatives and Adjunctive Therapies

When HRT is unsuitable or declined, or to complement it, other options include:

• Non-hormonal pharmacotherapy: Some SSRIs/SNRIs (paroxetine, venlafaxine, fluoxetine) and gabapentin can modestly reduce hot flushes. However, NICE advises against using SSRIs/SNRIs or clonidine as first-line therapy for vasomotor symptoms in lieu of HRT[58]. They may be offered if HRT is contraindicated or not tolerated, acknowledging their lesser efficacy. (Notably, paroxetine 7.5 mg daily is FDA-approved for hot flushes.) Clonidine or pregabalin are alternatives but have side effects.
• Vaginal Therapies: For isolated genitourinary symptoms, non-hormonal vaginal moisturizers and lubricants are first-line[21]. If these fail, vaginal oestrogen (cream, ring, tablet) is highly effective for vaginal dryness and urinary symptoms[21], with negligible systemic absorption. A newer SERM, ospemifene, is an oral non-hormonal alternative for dyspareunia (not available everywhere).
• Lifestyle and Complementary Approaches: General health measures can improve menopausal health: weight-bearing exercise, a calcium- and vitamin-D–rich diet, smoking cessation and limiting alcohol may protect bone and cardiovascular health[59]. Regular exercise and pelvic floor training help sexual function and genitourinary tone. Stress reduction, cooling techniques (fans, layered clothing), and cognitive-behavioral therapy (CBT) can lessen hot flush intensity and insomnia. Some women try herbal remedies (e.g. phytoestrogens like soy, black cohosh) or acupuncture; evidence is limited and they are not guideline-recommended.
• Adjunctive Therapies: For osteoporosis prevention when HRT is stopped, alternative drugs (bisphosphonates, denosumab, SERMs) should be considered. SSRIs/SNRIs or gabapentin may be added if HRT is partial or ineffective. Sometimes adding a testosterone trial can help residual sexual symptoms in women already on oestrogen-progestogen therapy[25].

Counselling and Shared Decision-Making

Effective HRT counselling involves personalized discussion of benefits, risks and alternatives[8][60]. Key points include:

• Explain Menopause and HRT Options: Describe menopause as a natural life stage; review typical symptoms (hot flushes, vaginal dryness, mood changes)[61]. Emphasize that HRT is treatment, not mandatory. Use simple terms or decision aids (NICE provides patient info and risk discussion tools)[8][60].
• Discuss Benefits vs Risks: Clarify that HRT is highly effective for symptom relief and bone protection, but has small increased risks (especially breast cancer and clotting). Use absolute figures if possible (e.g. “about 3–4 extra breast cancers per 1000 women per 5 years”[7]). Tailor to her specific factors (age, family history). Explain that younger women have a more favorable ratio. NICE advises individualized balancing of risk factors[62].
• Tailor to Patient: Inquire about personal values: how bothersome are symptoms, what does she fear most (e.g. cancer vs. fracture), and preferences (medication vs. natural methods). Document prior contraindications and family history (breast cancer, thrombosis). Confirm discussion of non-hormonal options if she is hesitant.
• Use a Decision Checklist: Ensure all domains are covered – symptom burden, HRT types/duration, monitoring plan, and fallback (non-HRT) options. Confirm the patient understands that HRT is not lifelong like a vaccine: it can be stopped or changed if needed[10]. Encourage questions and consider a written summary or support materials. NICE and the Faculty of Sexual and Reproductive Healthcare provide visual aids on risk/benefit profiles.
• Consent and Documentation: After discussion, obtain informed consent noting that she understands the rationale, benefits, and potential harms[8]. Provide the “Yellow Card” scheme for reporting side effects. Encourage her to report any unusual symptoms (breast lump, unexpected bleeding, leg swelling) promptly.

Special Populations

• Women over 65: Generally, HRT is only advised if severe symptoms persist and other causes have been excluded. Risks are higher; use the lowest dose transdermal route if HRT is tried. Advise that age 65+ is beyond standard “window” and higher stroke/dementia risk applies[32]. Do annual reviews to decide on continuation.
• Breast Cancer Survivors: Systemic HRT is contraindicated in current or past hormone-dependent breast cancer[44]. For women with severe menopausal symptoms and a history of breast cancer, first-line are non-hormonal methods[21]. If genitourinary atrophy is severe and unresponsive, very low-dose vaginal oestrogen may be considered with oncologist input[21]. Specialized “breast-unit” menopause clinics may use cautious approaches (e.g. low-dose topical creams).
• Transgender People: HRT in gender transition has its own protocols. Briefly: trans women receive oestrogen (oral, transdermal or intramuscular) plus an anti-androgen (spironolactone, cyproterone or GnRH agonist)[24]. Trans men receive testosterone (injectable or transdermal) with target male levels[24]. Endocrine Society guidelines recommend monitoring bone density, lipids, and prolactin as indicated. (NICE NG23 covers only those not currently on gender-affirming therapy, so refer separately to WPATH or endocrine guidelines for details.)
• Clotting Disorders: In women with known thrombophilia (e.g. Factor V Leiden) or strong VTE history, transdermal oestrogen is preferred if HRT is needed[45]. Combined with a levonorgestrel IUS (progestogen) may further reduce risk. Otherwise, non-hormonal methods are safer.
• Other Considerations: In women with migraine with aura, transdermal is safer[47]. Chronic renal failure or liver disease require specialist input. Patients with osteoporosis but no symptoms may still use HRT for bone protection if otherwise indicated. Those with severe hyperlipidaemia might benefit from HRT’s lipid effects, but statins also control that.

Prescribing and Practical Management

• Starting Doses: Initiate with a low dose and titrate up for symptom control. For example, a common regimen is oral estradiol 1–2 mg daily or a 25–50 µg/day transdermal patch, plus a progestogen if needed. (Exact doses are individualized; some guidelines simply advise “lowest effective dose.”) For progesterone, micronized progesterone 200 mg nightly (14 days/month) is typical if cyclic. Continuous combined regimens (daily progestogen) are used in older women to avoid bleeding.
• Dose Titration: Assess response at 3 months[10]. If symptoms persist, gradually increase dose or switch formulation (e.g. patch to higher-dose patch, or add testosterone). If breakthrough bleeding occurs on cyclic HRT, check timing/dose of progestogen; on continuous HRT, persistent spotting may require switching progestogen type or dose.
• Route Switching: If side effects occur, consider changing route. For example, nausea or migraines may improve by switching oral to transdermal[40]. If breast tenderness or bloating, a lower dose or micronized progesterone may help. Add a progestogen if on oestrogen alone with a uterus.
• Duration of Therapy: There is no fixed time limit on HRT use. BMS guidelines state that HRT may be continued “for as long as benefits outweigh risks”[11]. Some women use HRT for many years if symptomatic. However, it is standard practice to reassess annually and attempt tapering or stopping once symptoms resolve or if risk changes. Note: symptoms often recur on stopping[63], so planned tapering (over months) is preferred to abrupt cessation. If symptoms return after stopping, a brief restart is reasonable[63].
• Co-treatment and Continuation: If a woman remains on HRT (e.g. for osteoporosis prevention), continue to re-evaluate risks (age, new illness). For primary ovarian insufficiency, continue HRT until about age 51[22][23]. For women approaching menopause age who still have symptoms, continue as long as needed.
• Switching HRT Types: When switching from combined to oestrogen-only (after hysterectomy), ensure at least 2 weeks of oestrogen alone. If changing progestogen type due to side effects, observe for bleeding patterns.
• Medication Interactions: Some anticonvulsants or antibiotics can reduce oestrogen levels. Adjust dose or route if on interacting drugs.
• Patient Support: Advise women on the Yellow Card Scheme (MHRA) for adverse event reporting[64]. Provide educational leaflets or websites (e.g. NICE Information for Public) to reinforce discussion.

Summary of Formulations and Comparisons

Table 1: Comparison of HRT Formulations (advantages, disadvantages, indications)

Formulation	Hormone / Route	Pros (Advantages)	Cons (Disadvantages)
Oral oestrogen + progestogen	Pills (conjugated equine estrogens, ethinyl/E2 + MPA or micronized P4)	Easy dosing; well-studied; covers systemic symptoms and bone	↑Triglycerides, liver protein synthesis (↑ clotting factors)[13]; more nausea; higher VTE/stroke risk than patch
Transdermal oestrogen	Estradiol patch/gel/spray + oral or IUS progestogen	Steady blood levels; no first-pass effect; no VTE risk increase[13]; flexible dosing (patch strength variety)	Skin irritation; cost; patch adhesion issues (for some patients)
Vaginal oestrogen (local)	Estradiol/estriol vaginal cream, tablet or ring	Excellent for vaginal dryness, UTIs, dyspareunia; minimal systemic absorption (no progestogen needed)[14]	Only treats local symptoms; does not alleviate hot flushes or systemic issues
Sequential HRT	Daily oestrogen + cyclic progestogen (e.g. 14 days/month)	Monthly withdrawal bleed may reassure some women of not ‘losing’ uterus; improved mood in some women	Bleeding/spotting common; risk slightly higher if progestogen given <10 days/month[37]
Continuous Combined HRT	Daily oestrogen + continuous progestogen	No monthly bleeding (amenorrhea) in ~90% by 12 months[65]; better endometrial protection[36]	Irregular spotting common initially; amenorrhea may concern some women
IUS + Systemic HRT	Levonorgestrel intrauterine system + systemic oestrogen	Highly effective endometrial protection; easy (no pills); often no bleeding after 1–2 years	Insertion risk; irregular bleeding first 3–6 months
Tibolone (synthetic steroid)	Daily tablet	Relieves vasomotor/genitourinary symptoms; improves bone	Androgenic side effects (weight gain, acne); not for breast cancer survivors; no need for added progestogen (↓endometrium).
Testosterone (subcutaneous pellets)	(For female HSDD)	Monthly pellets can provide sustained hormone levels; improve libido	Invasive (insertion procedure); risk of androgen effects as above; unlicensed in most countries.
Levothyroxine (oral)	T4 tablets daily	Restores normal metabolism in hypothyroidism; well-tolerated	Overtreatment may cause tachycardia, osteoporosis; undertreatment leaves symptoms.

Table 2: Indications, Benefits and Risks by HRT Type

Use / Population	HRT Formulation	Main Benefits	Key Risks / Monitoring
Natural or surgical menopause (with uterus)	Systemic combined HRT (oestrogen + progestogen)	Eliminates hot flushes, night sweats; prevents bone loss[5]; improves quality of life	Breast cancer risk ↑ slightly over 5–10 years[7]; endometrial cancer decrease (with continuous); VTE ↑ with oral (avoid patch)[13]. Monitor breasts, metabolic profile.
Natural or surgical menopause (no uterus)	Oestrogen-only HRT (oral or patch)	As above (no need for progestogen); no increase in breast cancer risk[34] (vs combined)	VTE risk from oral oestrogen; endometrial cancer risk ↑ if uterus (not applicable); monitor as above.
Premature ovarian insufficiency	Combined or oestrogen-only (if no uterus); continue until ~51[22]	Maintains bone density; normalizes puberty/menopause timing[22][23]	Same as menopausal use, but younger age → lower absolute risk. Monitor growth/maturation if adolescent.
Post-oophorectomy (<50 yrs)	Combined HRT (if uterus) or oestrogen-only (if uterus absent)	Prevents immediate menopausal symptoms and osteoporosis[5][22]	Same as menopausal HRT (breast, VTE risks) but with greater urgency to replace hormones.
Male hypogonadism	Testosterone replacement (IM or topical)	Restores libido, muscle mass/strength, bone density; improves anemia/fatigue[24]	Erythrocytosis (monitor hematocrit)[19]; sleep apnea; prostate changes. Monitor testosterone level and hematocrit[19].
Hypothyroidism	Levothyroxine (oral)	Normalizes metabolism, energy, mental state	Over-replacement → atrial fibrillation, bone loss. Monitor TSH.
Transgender F→M	Testosterone (IM/gel)	Induce virilization (facial hair, voice deepening), stop menses[24]	As for male hypogonadism. Monitor T levels and hematocrit[19].
Transgender M→F	Oestrogen + anti-androgen	Feminization (breast growth, fat redistribution)	VTE, stroke risk (minimized by patch); prolactinoma risk. Monitor prolactin, lipids, glucose.
Osteoporosis prevention (female)	Systemic HRT	Increases bone density; reduces fracture risk[27]	Breast/VTE risks as above limit use to younger women at risk. Monitor BMD if used for bone.
Severe genitourinary symptoms	Local vaginal oestrogen	Resolves vaginal dryness, dyspareunia, itching	Minimal systemic effect; very low risk. No progestogen needed.

Monitoring Protocols and Follow-up

• Initial and Ongoing Reviews: Follow NICE guidance to review HRT at 3 months for efficacy and side effects, then annually[10]. Document symptom changes. If symptoms persist at 3 months, reassess dose or formulation. The annual review includes updating history and checking any new contraindications.
• Bleeding Patterns: Counsel women on expected bleeding with their regimen (monthly with sequential HRT; initial spotting with continuous). Any unscheduled or prolonged bleeding after 3–6 months should prompt investigation (e.g., endometrial sampling)[65]. Continual bleeding suggests the need to alter the progestogen.
• Laboratory Tests: Routine hormone assays (FSH, oestradiol) are not used to monitor therapy[57]. Instead, evaluate by symptom relief and side effects. At baseline and periodically (1–2 years), check blood pressure, lipids and fasting glucose in women on HRT, especially oral oestrogen. For thyroid HRT, check TSH ~8–12 weeks after any dose change, then yearly. For testosterone therapy, measure testosterone levels and hematocrit at 3–6 months and then annually[19]. Also monitor prostate-specific antigen (PSA) annually in men >50 on TRT (per endocrinology guidelines).
• Bone and Cancer Screening: Ensure age-appropriate breast (mammography), cervical, and other cancer screening is up to date. A baseline DEXA scan is reasonable in women starting long-term HRT with osteoporosis risk (then every 2–3 years or as clinically indicated)[59].
• Symptom Tracking: Use questionnaires (e.g. Menopause Rating Scale or MENQOL) to document symptom burden and inform decisions.

See Table 4 for a concise monitoring schedule.

Alternatives and Adjunct Therapies

When HRT is not used, the following may be offered:

• Lifestyle: Encourage weight-bearing exercise, diet rich in calcium and vitamin D, smoking cessation and alcohol moderation – all support bone and cardiovascular health. Advise pelvic floor exercises for genitourinary symptoms. Address sleep hygiene and stress reduction.
• Non-hormonal Medicines: As noted, SSRIs/SNRIs (paroxetine, venlafaxine), clonidine or gabapentin can be tried for hot flushes if HRT is contra, but have modest efficacy[58]. Vaginal lubricants and moisturizers are first-line for dryness. Ospemifene (a SERM) is an oral option for dyspareunia (not currently NICE-approved in all regions).
• Complementary Therapies: Black cohosh, red clover, and other phytoestrogens are used by some, but high-quality trials show minimal benefit. Omega-3 fatty acids, vitamin E, and herbal supplements are not proven. Cognitive-behavioural therapy and paced breathing can significantly reduce perceived hot flush bother[66].
• Adjuncts: In women on HRT who still have symptoms, clinicians may consider adding a testosterone patch (low dose) for hypoactive sexual desire[17]. SSRIs may also improve mood swings. For bone health, consider bisphosphonates or denosumab in older women or those stopping HRT.

Patient Counselling and Shared Decision-Making

Effective counselling is vital. Per NICE, care should be individualized with patient involvement[8][60]. Key counselling points include:

·       Explaining menopause and normal hormonal changes, emphasizing HRT is optional and based on symptoms[61].

·       Detailing the risks and benefits of HRT in understandable terms. For example: “HRT will likely eliminate hot flushes and strengthen your bones, but it carries a small extra chance of breast cancer or clots[7][13].” Use absolute risk numbers when possible (NICE has visual aids for this).

·       Clarifying that route matters: transdermal avoids clot risk[13]; that a uterus requires added progesterone to protect the womb.

·       Discussing alternatives (as above) and the strategy if she cannot or chooses not to take hormones. E.g., “If you can’t take HRT, SSRIs or gabapentin are other options for hot flushes, although they may be less effective.”

·       Setting expectations: side effects often improve in a few months[67]; also discussing how to handle them (e.g. changing dose/formulation).

·       Review screening: emphasize mammograms/cervical smears.

·       Use decision aids (e.g. NICE risk visual summaries) and provide written information (NHS Choice, NICE, or patient organizations).

·       Document the shared decision and patient preferences. NICE also recommends discussing fertility/contraception if pre-menopausal, and life/family plans.

By involving the patient in each step (shared decision-making)[8][60], she can weigh HRT’s personal value against its risks. Check understanding, encourage questions, and plan follow-up to revisit decisions.

Special Populations and Considerations

• Older Women (≥65 years): The benefit-risk shifts – risks rise and symptoms often wane. HRT may be offered only for severe symptoms in healthy older women, usually at low dose and via patch[6][32]. “Window of opportunity” effects fade by age 65. Dementia risk may increase if started late[32]. Annual reviews are crucial.
• Breast (and Other Hormone-sensitive) Cancer Survivors: Generally avoid systemic HRT[44]. Non-hormonal treatments are preferred. For refractory vaginal symptoms, NICE allows ultra-low-dose vaginal oestrogen (with oncologist approval)[21]. Women on tamoxifen or aromatase inhibitors should have specialist advice for any HRT use.
• Cardiovascular Disease (CVD): In women with known CVD, HRT is generally discouraged for primary or secondary prevention[28]. If used for symptoms, use lowest dose, transdermal route, and involve a cardiologist.
• Clotting Disorders: Factor V Leiden carriers or those with prior VTE may use transdermal oestrogen (lowest dose) if needed[45], since it minimally raises clot risk. Combined with a levonorgestrel IUS may be safest for endometrial protection. Otherwise manage symptoms non-hormonally.
• Migraine with Aura: Avoid oral oestrogen (mild contraindication) and prefer transdermal oestrogen or non-hormonal therapy[47].
• Renal or Hepatic Impairment: Liver disease can contraindicate oral HRT; transdermal is safer. Care with steroid clearance in liver failure. Adjust cortisol doses in severe kidney disease.
• Psychiatric and Cognitive Issues: No major role for HRT in treating depression/dementia[31]. However, perimenopausal mood lability may improve with HRT in some women. Screen for mood disorders and refer appropriately.

Table 3: Adverse Effects of HRT (common and serious)

Effect/Outcome	HRT Impact
Common side effects	Breast tenderness, headache, nausea, bloating, mood swings, fluid retention, spotting or irregular bleeding (especially first 3–6 months)[52][16]. Usually transient.
Breast cancer	Combined HRT slightly ↑ risk after ~5–10 years[7]; estrogen-only has minimal effect[34]. Absolute increase ~0.3–0.6% at 5 years.
Endometrial cancer	Unopposed oestrogen ↑ risk greatly; adding progestogen (especially continuous) prevents this[36].
Ovarian cancer	Slight increase (0.1–0.2%) with any HRT[38].
VTE (DVT/PE)	Oral HRT increases risk 2–3×[13]; transdermal does not raise risk[13]. Highest risk in first year, with obesity/smoking.
Stroke	Oral HRT in older women (≥60) increases risk (dose-dependent)[42]. Transdermal has little impact[42]. Overall absolute risk in <60’s is low.
Cardiovascular death	No significant change overall with HRT[29]. Timing (start age) may alter effects[6].
Type 2 diabetes	Generally decreased or unchanged risk on HRT[68][69]. (Estrogen improves insulin sensitivity.)
Gallstones	Increased incidence, especially with oral oestrogen (and tibolone) – counsel on healthy diet.
Migraine/Headache	May worsen headaches or migraines; transdermal may improve hormonal migraine.
Venous thrombosis (testosterone)	Testosterone has FDA warning for VTE in men[70], but risk is generally low; monitor hematocrit.

Table 4: Monitoring Schedule for HRT (examples)

Parameter	Baseline	Follow-Up	Notes
Symptoms & side effects review	Pre-start	3 months, then yearly[10]	Assess efficacy, tolerability.
Blood pressure, weight, BMI	Pre-start	At 3m, then every visit	Control hypertension.
Mammogram	Per guidelines (age)	As per screening schedule	More frequent only if indicated.
Pelvic exam/cervical smear	As per guidelines	As per screening	Unaffected by HRT.
Breast exam/mammogram (50+)	Pre-start or recent	Annually (usual screening intervals)	Mammogram unaffected by HRT.
Bone density (DEXA)	If high risk	Every 2–3 years if on HRT for bone issues
Lipids, fasting glucose	Pre-start	6–12 months, then annually if needed	Check metabolic effects.
Liver function tests	Pre-start (if risk)	6-12 months if on oral oestrogen	Transdermal less impact.
Oestradiol/progesterone levels	Not needed	Not needed	Titrate by symptoms, not levels.
Testosterone level (men on TRT)	Baseline total T, free T (if indicated)	3–6 months, then annually[19]	Aim for mid-normal range.
Hematocrit (men on TRT)	Baseline	3–6 months, then annually[19]	Stop therapy if >54%.
TSH (thyroid replacement)	Baseline	6–8 weeks after dose change, then 6–12 mo	Target mid-normal range.
Endometrial monitoring (HRT use)	Baseline TVUS if abnormal bleed	Symptom-driven; investigate any abnormal bleeding[65]	Annual ultrasound not routine.

Controversies and Gaps in Evidence

·       Cardiovascular “Timing”: Debate continues on the “window” for HRT initiation. Observationally, early start (<10 years post-menopause) may reduce coronary risk, while late start may harm[6]. RCT data (WHI) included older women, so results are mixed. Further research is ongoing.

·       HRT and Cognition: No consensus that HRT prevents dementia; some analyses hint at harm if started late[32]. The NIHR-funded “ESTEEM” trial on testosterone for cognition is in progress.

·       Breast Cancer and HRT: The small increase in breast cancer risk with combined HRT is accepted, but questions remain about differences between progestogens (micronized progesterone vs synthetic)[50]. Long-term outcomes after HRT-associated breast cancer need study.

·       Breast Cancer Survivors: Need more data on non-systemic HRT (e.g. tibolone, low-dose estrogen) for severe symptoms in survivors. Current practice is very cautious.

·       Testosterone in Women: Lack of licensed formulations makes practice variable. Evidence for benefits on mood/energy is limited; ongoing trials (like Oxford’s TEACH study) may clarify risks/benefits.

·       Duration of Therapy: No large RCTs have evaluated very long-term (>10 year) HRT use. Observationally many women use HRT for decades, but official guidance is based on balancing risk which becomes harder to quantify with very long use.

·       Bioidentical Hormones: “Compounded bioidentical” preparations (blends of hormones) are popular but not evidence-based; they are neither recommended by guidelines nor FDA-approved. Quality and safety are uncertain.